Gut microbiota-modulating interventions in paediatric type 1 diabetes: a systematic review and meta-analysis

This study systematically reviewed and meta-analysed all available randomised controlled trials (RCTs) testing whether probiotics, prebiotics, or synbiotics can improve health outcomes in children and teenagers with type 1 diabetes (T1D). Type 1 diabetes is an autoimmune condition where the immune system destroys insulin-producing beta cells, and emerging evidence suggests the gut microbiome plays a role in disease progression and glycaemic regulation. The researchers pooled data from 12 RCTs involving 808 paediatric participants and found that these microbiota-modulating interventions significantly reduced two key markers of blood sugar control — glycated haemoglobin (HbA1c) and fasting blood glucose — compared with placebo or control. However, no significant effects were detected for total daily insulin dose or C-peptide, the latter being a marker of residual insulin-secreting capacity. Immune, microbiome composition, and gut barrier outcomes looked promising in individual trials but could not be combined statistically due to inconsistent reporting. The overall evidence base is limited by heterogeneity across interventions, doses, and study designs, meaning no specific probiotic formulation can currently be recommended. The authors conclude that while the glycaemic signals are encouraging, larger, rigorously designed paediatric trials with standardised protocols are urgently needed before these interventions can be translated into clinical practice.

• Pooled meta-analysis of 12 RCTs (n=808 paediatric participants) showed a statistically significant reduction in glycated haemoglobin (HbA1c) with probiotic/prebiotic/synbiotic interventions versus control, though exact pooled effect sizes were not reported in the abstract.
• Fasting blood glucose was also significantly reduced in the pooled analysis, suggesting adjunctive benefit for short-term glycaemic regulation beyond HbA1c.
• No significant effects were detected for total daily insulin dose or C-peptide levels, indicating these interventions did not demonstrably preserve residual beta-cell function or reduce insulin requirements in paediatric T1D.
• Immune-inflammatory markers, gut microbiota composition metrics, and intestinal permeability outcomes showed possible benefits across individual trials, but inconsistent reporting across studies prevented quantitative pooling.
• Substantial clinical and methodological heterogeneity — including variation in probiotic strains, doses, durations, and background insulin regimens — limits the certainty of all pooled estimates.

This was a systematic review and meta-analysis conducted in accordance with PRISMA 2020 guidelines. Four major databases (PubMed/MEDLINE, Scopus, Web of Science, and CENTRAL) were searched from inception through 28 February 2026, restricted to RCTs testing oral probiotics, prebiotics, or synbiotics in participants aged ≤19 years with confirmed type 1 diabetes. Primary outcomes were HbA1c, fasting blood glucose, total daily insulin dose, and C-peptide; secondary outcomes encompassing immune-inflammatory, microbiota-compositional, intestinal permeability, and safety endpoints were synthesised narratively where quantitative pooling was not feasible. Twelve RCTs totalling 808 paediatric participants met inclusion criteria; intervention formulations, doses, and durations varied across trials.

The meta-analysis is substantially constrained by clinical heterogeneity — diverse probiotic strains, prebiotic substrates, dosing regimens, intervention durations, and co-interventions (e.g., insulin delivery method) make it difficult to attribute pooled effects to any specific mechanism or formulation. Inconsistent reporting of secondary outcomes (immune markers, microbiota composition, gut permeability) precluded quantitative synthesis for the endpoints most mechanistically relevant to T1D pathogenesis. The included trials are predominantly small and short-term, raising concerns about publication bias and the durability of any glycaemic benefit over clinically meaningful timeframes. Future experiments should prioritise multi-centre RCTs with pre-specified, harmonised microbiome and immune endpoints, adequate power to detect C-peptide differences, and follow-up of at least 12 months to assess whether glycaemic improvements are sustained.

This review sits at the intersection of microbiome intervention science and paediatric metabolic disease, directly extending the corpus's focus on microbiota-modulating strategies across disease contexts. It parallels [§76], which examines dietary fibre (prebiotic) effects on carbohydrate metabolism and gut microbiota in diabetes, though that work targets type 2 diabetes in adults — together the two papers highlight how fibre and microbiota manipulation influence glycaemic pathways across both major diabetes subtypes. The mechanistic framing of microbiome-host immune crosstalk in T1D also connects to [§87], which maps gut microbiota regulation of systemic inflammatory and compensatory anti-inflammatory response syndromes, providing a plausible immunological scaffold for why probiotic interventions might modulate T1D autoimmunity. The broader translational challenge identified here — that promising preclinical and early-phase signals do not yet translate into clear clinical recommendations — resonates with the caution articulated in [§100], which frames the human microbiome field as being at a critical translational crossroads requiring ecological and causal rigor. Finally, the paediatric focus and the finding that specific microbial interventions can shift host physiology in children parallels [§75], which examines probiotic influences on early gut microbial colonisation, underscoring that developmental stage is a key moderator of microbiome intervention outcomes.

• The Effect of OptiFibre Dietary Fiber on Carbohydrate Metabolism and Intestinal Microbiota Metabolism in Patients With Type 2 Diabetes Mellitus
  Directly parallel intervention logic — dietary fibre as a prebiotic modulates gut microbiota and carbohydrate metabolism in diabetes — but targets type 2 diabetes in adults, enabling a cross-type and cross-age comparison of microbiota-glycaemia mechanisms.
• Influence of Probiotics on Early Gut Microbial Colonization
  Examines probiotic effects on gut microbial colonisation in paediatric populations, making it the closest available comparator for understanding how developmental stage and baseline microbiome maturity shape the response to microbiota-modulating interventions in children.
• Gut Microbiota Regulates Systemic Inflammatory Response and Compensatory Anti-Inflammatory Response Syndromes by Targeting PF4+ Macrophages in Acute Pancreatitis
  Provides a mechanistic immune-inflammatory framework — gut microbiota regulation of systemic inflammatory response syndromes — that could explain why probiotic/synbiotic interventions in paediatric T1D might affect immune markers even when beta-cell preservation (C-peptide) remains unchanged.
• The human microbiome at translational crossroads: an ecological and causal perspective
  Frames the entire microbiome intervention field from a translational and causal-inference perspective, directly contextualising why this meta-analysis — despite pooling 12 RCTs — still cannot recommend a specific formulation, and what methodological standards are needed to move the field forward.
• Psyllium in Pediatric IBS
  Examines a prebiotic intervention (psyllium) in a paediatric gastrointestinal condition, offering a methodological comparator for how paediatric microbiota-targeted RCTs are designed, powered, and reported in an age group where trial conduct is inherently challenging.